Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metronidazole - Appili Therapeutics

Next Previous
Drug Profile

Metronidazole - Appili Therapeutics

Alternative Names: ATI 1501; LIKMEZ

Latest Information Update: 07 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Appili Therapeutics
  • Class Antibacterials; Antiprotozoals; Nitroimidazoles; Radiosensitisers; Skin disorder therapies; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anaerobic infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed Amoebiasis; Anaerobic infections; Trichomoniasis

Most Recent Events

  • 28 Apr 2025 Appili Therapeutics has patent protection for Metronidazole in USA and Mexico
  • 28 Feb 2024 No recent reports of development identified for phase-I development in Anaerobic-infections(In volunteers) in Canada (PO, Suspension)
  • 30 Nov 2023 Launched for Amoebiasis (In adolescents, In children, In infants, In neonates, In adults) in USA (PO) - First global launch

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top